E.d. Bellis

For the first time in nearly two decades, the Food and Drug Administration (FDA) has approved a drug to treat the horrible disease known as Alzheimer's which affects 6 million Americans right now and is expected to impact 13 million within the next 30 years. This new drug called Aducanumab and developed by Biogen targets the plaque that affects brain cells and was approved amidst some controversy. In this episode we cover this breaking news and play clips from the Biogen CEO who defends the $56,000 annual price. As a bonus in this segment we discuss how you can capitalize on rebate programs to save thousands on cost sharing expenses. For more visit our facebook page: facebook.com/americashealthcarechallenge